Cite
APA Citation
Zhang, J., Hussein, M., Kao, S., Clay, T., Singhal, N., Kim, H., Cho, E., Shim, B., Lee, Y., Lee, G., Zhao, J., Yu, Y., Sun, M., Lin, C., Yang, T., Chang, G., Zheng, H., Tan, W., & Spigel, D. (n.d.). 148P AdvanTIG-105: Phase Ib dose-expansion study of ociperlimab (OCI) + tislelizumab (TIS) with chemotherapy in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC). Immuno-oncology technology, 16, . http://access.bl.uk/ark:/81055/vdc_100172206555.0x00000e